Publication | Closed Access

Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery

Surgical OncologyPancreatic CancerFacilities SpecializingGastrointestinal OncologyMedicinePancreatic SurgerySurgeryOncologyRadiation OncologyCancer ResearchNeoadjuvant ChemotherapyClinical Impact